Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including ...

Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 7-10. Improving access to life-saving therapies for blood disorders is the theme ...

A new thesis from Karolinska Institutet shows the effectiveness of flexible parametric survival models in modeling multiple ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

The myelodysplastic syndromes (MDS ... indeterminate potential and its association with the incidence of myeloid neoplasms (MN) remains to be explored. Here, the authors suggest that heteroplasmy ...

The models were tested ... The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these individuals have a high mortality ...

If you or someone you know has just been diagnosed with myelodysplastic syndrome (MDS), this short guide can help. Find information on myelodysplastic syndrome here. Cancer can start any place in the ...

A retrospective analysis on newborn screening for spinal muscular atrophy (SMA) provides further evidence for the benefits of early identification and treatment of the disease. A recent analysis ...

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms ...

Dr. Mikkael Sekeres is a co-author. High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms. Dr. Mikkael Sekeres is a co-author. CCL8/CCL13-Producing Tumor ...

Momelotinib's higher pharmacy costs outweigh its clinical benefits and lower transfusion costs compared with ruxolitinib. Ruxolitinib's total cost of care is significantly lower over 6-month, 1 ...